Key result
Correction fixes an image overlap regarding EPZ5676 and EGFR expression without altering original conclusions.
This is a correction notice for a figure in a preclinical study on peritoneal fibrosis, which does not alter the original conclusions.
Answers are grounded in this paper and cite their sources.
Image correction upholds DOT1L fibrosis conclusions; leaves open therapeutic targeting of protein tyrosine kinases in peritoneal models.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Tao et al. (2026) studied Peritoneal fibrosis. EPZ5676 (DOT1L inhibitor) vs. Control (starved without medication) was evaluated on Expression and activation of EGFR in peritoneal mesothelial cells. A correction was published to fix an image overlap in Figure 5e regarding the effect of DOT1L inhibitor EPZ5676 on EGFR expression, which does not alter the original study's conclusions.
Synapse has enriched 10 related papers. Consider them for comparative context: